quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:32:24·56d
SECFiling
NCR Voyix Corporation logo

NCR Voyix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

VYX· NCR Voyix Corporation
Miscellaneous
Original source

Companies

  • VYX
    NCR Voyix Corporation
    Miscellaneous

Recent analyst ratings

  • Oct 14UpdateGoldman$14.00
  • Jun 12UpdateStifel$16.00
  • Mar 18UpdateGoldman$14.00
  • Mar 12UpdateNorthcoast$17.00
  • Dec 4UpdateNeedham$22.00

Related

  • SEC2d
    SEC Form DEFA14A filed by NCR Voyix Corporation
  • SEC2d
    SEC Form DEF 14A filed by NCR Voyix Corporation
  • PR38d
    NCR Voyix to Sell Bank Technology Solutions Business in Japan
  • INSIDER38d
    EVP & CFO Webb-Walsh Brian J. converted options into 27,012 shares and covered exercise/tax liability with 12,674 shares, increasing direct ownership by 8% to 190,551 units (SEC Form 4)
  • INSIDER38d
    EVP, General Counsel & Secrtry Sterrett Kelli converted options into 20,259 shares and covered exercise/tax liability with 9,724 shares, increasing direct ownership by 26% to 51,206 units (SEC Form 4)
  • INSIDER38d
    SVP & Chief Accounting Officer Wise James Michael converted options into 2,701 shares and covered exercise/tax liability with 942 shares, increasing direct ownership by 18% to 11,521 units (SEC Form 4)
  • INSIDER38d
    President & CEO Kelly James G converted options into 26,731 shares, increasing direct ownership by 31% to 113,753 units (SEC Form 4)
  • INSIDER38d
    EVP & President, Restaurants Tadele Beimnet converted options into 12,156 shares and covered exercise/tax liability with 3,912 shares, increasing direct ownership by 28% to 37,778 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022